Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Hines, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 55 people, planned
- Started
- 20 May 2024
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- intermittent theta burst stimulation
- placebo intermittent theta burst stimulation
- Record updated
- 14 April 2026
Who can take part
- Age
- 22 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- 22-65 years of age
- can read and speak English
- meets criteria for mTBI according to the symptom attribution and classification (SACA) scale
- Has a C-SSRS (suicidal ideation rating) of >1 within the past month
- Has a history of impulsivity documented in the medical chart and/or a score of >20 on the UPPS-P negative urgency impulsivity subscale
Who cannot take part
- Has contraindications to MRI (i.e., claustrophobia, ferromagnetic metal implants)
- Is within 12 weeks of a major surgery or operation
- Has contraindications to iTBS (i.e., epilepsy)
- Has an active substance use disorder per the DSM-V criteria
- Has a history of moderate to severe TBI
- Has a history of non-traumatic neuroinjury (i.e., stroke, neurosurgery, hemorrhage)
- Has a history of, or current psychosis not due to an external cause
- Has an active, unstable medical condition
- Is pregnant
- Is within 1 year of TBI
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 22 and 65 years old?
Where in United States
- Edward Hines Jr. VA Hospital, Hines, ILHines, United StatesContact: William Wolf, PhDTaking people
About the trial
What the trial wants to find out
The investigators hope to develop a treatment for suicidal ideation (SI), impulsivity and functional impairments (such as difficulties in social and work settings) that occur after a mild traumatic brain injury (mTBI). These conditions have been shown to be linked. The investigators are using a high-powered magnetic pulse, called intermittent theta burst stimulation (iTBS) applied to the head to see if it can improve these symptoms. The high-powered magnetic pulse causes certain cells in the brain to activate, which seems to strengthen connections between parts of the brain. The purpose of this research is to gather early information on the safety and effectiveness of iTBS provided to the front of the head for impulsivity, SI and functional deficits after mTBI. The investigators plan to use the data collected in this study to develop larger studies in the future. iTBS is FDA approved, but not for these specific symptoms, or in the specific location the investigators are placing it. The investigators are testing to see if its effective for the above conditions when applied to the front of the head.
The 2 groups in the trial
- active iTBSExisting treatment, for comparison
Subjects receiving active iTBS treatment
Treatment: intermittent theta burst stimulation
- placebo iTBSPlacebo, for comparison
Subjects receiving placebo (sham) iTBS treatment
Treatment: placebo intermittent theta burst stimulation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neuromodulation for Impulsivity and Suicidality in Veterans With Mild Traumatic Brain Injury and Common Co-occurring Mental Health Conditions
- Criteria questions
- Built from NCT05647044, who can take part
- Publications
- Record updated
- 14 April 2026